Market News AIOpen the app

DNLI stock news · Denali Therapeutics

Stories about Denali Therapeutics (DNLI) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for DNLI

Follow Denali Therapeutics (DNLI) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for DNLI
Free on the App Store and Google Play, or on the web.
  1. Oct 30, 2026, 2:40 PM ET · Market

    Denali Therapeutics won the 2026 Prix Galien USA Award for its product AVLAYAH.

    Good for DNLI

    Denali Therapeutics won a 2026 award for AVLAYAH, adding outside recognition to its approved treatment. This is a modest positive for the company.

  2. Oct 12, 2026, 8:05 AM ET · Results

    Denali Therapeutics shared details from its earnings call for the second quarter of 2026.

    Good for DNLI

    Denali’s first full Avlea sales quarter brought in $3.6 million. Its Alzheimer’s programs and over $1.1 billion in cash support a favorable outlook, though data are not due until 2027.